Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.

Biglan, Kevin; Munsie, Leanne; Svensson, Kjell A; Ardayfio, Paul; Pugh, Melissa; Sims, John; Brys, Miroslaw

Biglan, Kevin; Munsie, Leanne; Svensson, Kjell A; Ardayfio, Paul; Pugh, Melissa; Sims, John; Brys, Miroslaw.

Affiliation

Biglan K; Eli Lilly and Company, Indianapolis, Indiana, USA.
Munsie L; Eli Lilly and Company, Indianapolis, Indiana, USA.
Svensson KA; Eli Lilly and Company, Indianapolis, Indiana, USA.
Ardayfio P; Eli Lilly and Company, Indianapolis, Indiana, USA.
Pugh M; Eli Lilly and Company, Indianapolis, Indiana, USA.
Sims J; Eli Lilly and Company, Indianapolis, Indiana, USA.
Brys M; Eli Lilly and Company, Indianapolis, Indiana, USA.

Mov Disord ; 37(3): 513-524, 2022 03.

Article in En | MEDLINE | ID: mdl-34859493

Subject(s)

Alzheimer Disease; Lewy Body Disease; Neuroprotective Agents; Cognition; Double-Blind Method; Humans; Lewy Body Disease/drug therapy; Neuroprotective Agents/therapeutic use

Key words

Lewy body dementia; cognition; dopamine D1 receptor; motor impairment; selective positive allosteric modulator (PAM)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Neuroprotective Agents / Lewy Body Disease / Alzheimer Disease Type of study: Clinical_trials Limits: Humans Language: En Journal: Mov Disord Journal subject: NEUROLOGIA Year: 2022 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google